Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 60Breast Neoplasms 54Ovarian Neoplasms 35Triple Negative Breast Neoplasms 28Lung Neoplasms 25Fallopian Tube Neoplasms 24Endometrial Neoplasms 24Neoplasm Metastasis 22Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 19Neoplasms 15Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 12Carcinoma, Ovarian Epithelial 10Stomach Neoplasms 9Head and Neck Neoplasms 9Carcinoma 9Colorectal Neoplasms 8Adenocarcinoma Of Esophagus 7Adenocarcinoma 7Peritoneal Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Respiratory Tract Neoplasms 3Recurrence 3

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × Paclitaxel × 90 days × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡